FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2121082147> ?p ?o ?g. }

• W2121082147 abstract "Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder. The role of pharmacotherapy for IBS is limited and focused mainly on symptom control.The objective of this systematic review was to evaluate the efficacy of bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.Computer assisted structured searches of MEDLINE, EMBASE, The Cochrane library, CINAHL and PsychInfo were conducted for the years 1966-2009. An updated search in April 2011 identified 10 studies which will be considered for inclusion in a future update of this review.Randomized controlled trials comparing bulking agents, antispasmodics or antidepressants with a placebo treatment in patients with irritable bowel syndrome aged over 12 years were considered for inclusion. Only studies published as full papers were included. Studies were not excluded on the basis of language. The primary outcome had to include improvement of abdominal pain, global assessment or symptom score.Two authors independently extracted data from the selected studies. Risk Ratios (RR) and Standardized Mean Differences (SMD) with 95% confidence intervals (CI) were calculated. A proof of practice analysis was conducted including sub-group analyses for different types of bulking agents, spasmolytic agents or antidepressant medication. This was followed by a proof of principle analysis where only the studies with adequate allocation concealment were included.A total of 56 studies (3725 patients) were included in this review. These included 12 studies of bulking agents (621 patients), 29 of antispasmodics (2333 patients), and 15 of antidepressants (922 patients). The risk of bias was low for most items. However, selection bias is unclear for many of the included studies because the methods used for randomization and allocation concealment were not described. No beneficial effect for bulking agents over placebo was found for improvement of abdominal pain (4 studies; 186 patients; SMD 0.03; 95% CI -0.34 to 0.40; P = 0.87), global assessment (11 studies; 565 patients; RR 1.10; 95% CI 0.91 to 1.33; P = 0.32) or symptom score (3 studies; 126 patients SMD -0.00; 95% CI -0.43 to 0.43; P = 1.00). Subgroup analyses for insoluble and soluble fibres also showed no statistically significant benefit. Separate analysis of the studies with adequate concealment of allocation did not change these results. There was a beneficial effect for antispasmodics over placebo for improvement of abdominal pain (58% of antispasmodic patients improved compared to 46% of placebo; 13 studies; 1392 patients; RR 1.32; 95% CI 1.12 to 1.55; P < 0.001; NNT = 7), global assessment (57% of antispasmodic patients improved compared to 39% of placebo; 22 studies; 1983 patients; RR 1.49; 95% CI 1.25 to 1.77; P < 0.0001; NNT = 5) and symptom score (37% of antispasmodic patients improved compared to 22% of placebo; 4 studies; 586 patients; RR 1.86; 95% CI 1.26 to 2.76; P < 0.01; NNT = 3). Subgroup analyses for different types of antispasmodics found statistically significant benefits for cimteropium/ dicyclomine, peppermint oil, pinaverium and trimebutine. Separate analysis of the studies with adequate allocation concealment found a significant benefit for improvement of abdominal pain. There was a beneficial effect for antidepressants over placebo for improvement of abdominal pain (54% of antidepressants patients improved compared to 37% of placebo; 8 studies; 517 patients; RR 1.49; 95% CI 1.05 to 2.12; P = 0.03; NNT = 5), global assessment (59% of antidepressants patients improved compared to 39% of placebo; 11 studies; 750 patients; RR 1.57; 95% CI 1.23 to 2.00; P < 0.001; NNT = 4) and symptom score (53% of antidepressants patients improved compared to 26% of placebo; 3 studies; 159 patients; RR 1.99; 95% CI 1.32 to 2.99; P = 0.001; NNT = 4). Subgroup analyses showed a statistically significant benefit for selective serotonin releasing inhibitors (SSRIs) for improvement of global assessment and for tricyclic antidepressants (TCAs) for improvement of abdominal pain and symptom score. Separate analysis of studies with adequate allocation concealment found a significant benefit for improvement of symptom score and global assessment. Adverse events were not assessed as an outcome in this review.There is no evidence that bulking agents are effective for treating IBS. There is evidence that antispasmodics are effective for the treatment of IBS. The individual subgroups which are effective include: cimetropium/dicyclomine, peppermint oil, pinaverium and trimebutine. There is good evidence that antidepressants are effective for the treatment of IBS. The subgroup analyses for SSRIs and TCAs are unequivocal and their effectiveness may depend on the individual patient. Future research should use rigorous methodology and valid outcome measures." @default.
• W2121082147 created "2016-06-24" @default.
• W2121082147 creator A5028188797 @default.
• W2121082147 creator A5029555061 @default.
• W2121082147 creator A5039067937 @default.
• W2121082147 creator A5043646452 @default.
• W2121082147 creator A5074671267 @default.
• W2121082147 creator A5090103426 @default.
• W2121082147 date "2011-08-10" @default.
• W2121082147 modified "2023-10-13" @default.
• W2121082147 title "Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome" @default.
• W2121082147 cites W102111670 @default.
• W2121082147 cites W127748566 @default.
• W2121082147 cites W138179200 @default.
• W2121082147 cites W138682165 @default.
• W2121082147 cites W1486772481 @default.
• W2121082147 cites W149139251 @default.
• W2121082147 cites W1503441866 @default.
• W2121082147 cites W1513017021 @default.
• W2121082147 cites W15241020 @default.
• W2121082147 cites W152590838 @default.
• W2121082147 cites W1552656977 @default.
• W2121082147 cites W1588206639 @default.
• W2121082147 cites W162043547 @default.
• W2121082147 cites W172308243 @default.
• W2121082147 cites W17884049 @default.
• W2121082147 cites W1837429672 @default.
• W2121082147 cites W183978064 @default.
• W2121082147 cites W1907042839 @default.
• W2121082147 cites W193362411 @default.
• W2121082147 cites W1955481851 @default.
• W2121082147 cites W1963986741 @default.
• W2121082147 cites W1965177436 @default.
• W2121082147 cites W1965677229 @default.
• W2121082147 cites W1966028527 @default.
• W2121082147 cites W1966290322 @default.
• W2121082147 cites W1972086588 @default.
• W2121082147 cites W1973096358 @default.
• W2121082147 cites W1977091664 @default.
• W2121082147 cites W1977149916 @default.
• W2121082147 cites W1979220925 @default.
• W2121082147 cites W1980847674 @default.
• W2121082147 cites W1980897225 @default.
• W2121082147 cites W1982400939 @default.
• W2121082147 cites W1983697664 @default.
• W2121082147 cites W1984511616 @default.
• W2121082147 cites W1985025206 @default.
• W2121082147 cites W1988485729 @default.
• W2121082147 cites W1988870110 @default.
• W2121082147 cites W198974309 @default.
• W2121082147 cites W1990577459 @default.
• W2121082147 cites W1991811818 @default.
• W2121082147 cites W1991905967 @default.
• W2121082147 cites W1997297098 @default.
• W2121082147 cites W1997714686 @default.
• W2121082147 cites W1997974061 @default.
• W2121082147 cites W1998058162 @default.
• W2121082147 cites W1998314061 @default.
• W2121082147 cites W2001697686 @default.
• W2121082147 cites W2004712304 @default.
• W2121082147 cites W2005575554 @default.
• W2121082147 cites W2005939269 @default.
• W2121082147 cites W2006544724 @default.
• W2121082147 cites W2006744757 @default.
• W2121082147 cites W2006750191 @default.
• W2121082147 cites W2007301983 @default.
• W2121082147 cites W2011627484 @default.
• W2121082147 cites W2012237650 @default.
• W2121082147 cites W2013223817 @default.
• W2121082147 cites W2013274785 @default.
• W2121082147 cites W2014571389 @default.
• W2121082147 cites W2016598086 @default.
• W2121082147 cites W2016700607 @default.
• W2121082147 cites W2017149768 @default.
• W2121082147 cites W2017991480 @default.
• W2121082147 cites W2018061064 @default.
• W2121082147 cites W2018283964 @default.
• W2121082147 cites W2020862319 @default.
• W2121082147 cites W2021938002 @default.
• W2121082147 cites W2022359234 @default.
• W2121082147 cites W2022429999 @default.
• W2121082147 cites W2026751952 @default.
• W2121082147 cites W2027063307 @default.
• W2121082147 cites W2029108089 @default.
• W2121082147 cites W2029581673 @default.
• W2121082147 cites W2030439201 @default.
• W2121082147 cites W2030669579 @default.
• W2121082147 cites W2032382790 @default.
• W2121082147 cites W2033600566 @default.
• W2121082147 cites W2036773306 @default.
• W2121082147 cites W2038615246 @default.
• W2121082147 cites W203923061 @default.
• W2121082147 cites W2040531526 @default.
• W2121082147 cites W2041472403 @default.
• W2121082147 cites W2042884393 @default.
• W2121082147 cites W2045329496 @default.
• W2121082147 cites W2046456501 @default.
• W2121082147 cites W2050360760 @default.
• W2121082147 cites W2052159025 @default.
• W2121082147 cites W2052559824 @default.

• next